Syndax Pharmaceuticals Inc (SNDX)
20.30
-0.62
(-2.96%)
USD |
NASDAQ |
May 17, 16:00
20.30
0.00 (0.00%)
After-Hours: 20:00
Syndax Pharmaceuticals Revenue (Quarterly)
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2021 | 126.58M |
| September 30, 2021 | 12.38M |
| June 30, 2021 | 0.379M |
| March 31, 2021 | 0.379M |
| December 31, 2020 | 0.379M |
| September 30, 2020 | 0.379M |
| June 30, 2020 | 0.379M |
| March 31, 2020 | 0.379M |
| December 31, 2019 | 0.379M |
| September 30, 2019 | 0.379M |
| June 30, 2019 | 0.379M |
| March 31, 2019 | 0.379M |
| December 31, 2018 | 0.379M |
| September 30, 2018 | 0.379M |
| Date | Value |
|---|---|
| June 30, 2018 | 0.379M |
| March 31, 2018 | 0.379M |
| December 31, 2017 | 1.193M |
| September 30, 2017 | 0.305M |
| June 30, 2017 | 0.305M |
| March 31, 2017 | 0.305M |
| December 31, 2016 | 0.305M |
| September 30, 2016 | 0.305M |
| June 30, 2016 | 0.305M |
| March 31, 2016 | 0.305M |
| December 31, 2015 | 0.305M |
| September 30, 2015 | 0.305M |
| June 30, 2015 | 0.017M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
0.379M
Minimum
Jun 2019
126.58M
Maximum
Dec 2021
12.94M
Average
0.379M
Median
Jun 2019
Revenue (Quarterly) Benchmarks
| Geron Corp | 0.304M |
| Verastem Inc | -- |
| Karyopharm Therapeutics Inc | 33.13M |
| Crinetics Pharmaceuticals Inc | 0.64M |
| Arvinas Inc | 25.30M |
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | -72.40M |
| Total Expenses (Quarterly) | 79.51M |
| EPS Diluted (Quarterly) | -0.85 |
| Enterprise Value | 1.281B |
| Earnings Yield | -15.87% |
| Operating Earnings Yield | 1.74% |
| Normalized Earnings Yield | 2.119 |